Adaptation of an in vitro one-compartment pharmacodynamic chemostat for testing efficacy of ceftazidime against Burkholderia pseudomallei outside a BSL3 facility
Non-clinical pharmacokinetic-pharmacodynamic (PKPD) models are crucial in the initial design of drug-dosage regimens and in drug development but has rarely been employed for testing high-risk organisms due to stringent handling procedures. Burkholderia pseudomallei is classified as a Tier 1 select a...
Saved in:
Main Authors: | Hana Farizah Zamri, Mohammad Ridhuan Mohd Ali, Ahmad Izzan Irfan Sha'ari, Nurul Husna Mohd Mazalan, Norazah Ahmad, Nur Asyura Nor Amdan, Nusaibah Abdul Rahim, Zakuan Zainy Deris |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-06-01
|
Series: | MethodsX |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2215016125000159 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibody and serum bactericidal response to Burkholderia pseudomallei in acute localized and septicemic melioidosis cases with diabetes mellitus
by: Sraboni Mazumder, et al.
Published: (2025-01-01) -
BETTER OUTCOME OF HIGH-DOSE CEFTAZIDIME IN HEMATO – ONCOLOGICAL PATIENTS WITH INFECTIONS CAUSED BY EXTENSIVELY DRUG-RESISTANT PSEUDOMONAS AERUGINOSA
by: Alzbeta Zavrelova, et al.
Published: (2022-12-01) -
Ceftazidime–avibactam for the Treatment of Intra-abdominal Sepsis and Urosepsis: A Retrospective Hospital-based Study in India
by: Prachee Sathe, et al.
Published: (2024-12-01) -
Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Cohort Study
by: Thamer A. Almangour, et al.
Published: (2025-01-01) -
Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin
by: Jingli Lu, et al.
Published: (2025-01-01)